Statements (189)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquired_by |
gptkb:Abb_Vie
|
| gptkbp:acquisition |
$63 billion
|
| gptkbp:acquisition_year |
gptkb:2017
gptkb:2020 |
| gptkbp:advertising |
Dr. Lisa D. Williams
|
| gptkbp:awards |
various industry awards
sustainability awards innovation awards philanthropy awards best workplace awards |
| gptkbp:brand_recognition |
high
|
| gptkbp:business_model |
B2 B and B2 C
|
| gptkbp:ceo |
gptkb:David_M._Pyott
gptkb:David_Pyott gptkb:Richard_A._Gonzalez |
| gptkbp:clinical_trial |
ongoing
extensive invests heavily phase I trials phase II trials phase III trials various phases of clinical trials extensive clinical research programs numerous ongoing |
| gptkbp:community_engagement |
gptkb:healthcare_access
community health initiatives |
| gptkbp:community_involvement |
philanthropy initiatives
|
| gptkbp:community_outreach |
health education programs
employee volunteer programs support for local charities |
| gptkbp:competitors |
gptkb:Merck
gptkb:Johnson_&_Johnson gptkb:Bristol-Myers_Squibb gptkb:Pfizer gptkb:Novartis |
| gptkbp:conducts_research_on |
Dr. Scott Whitcup
|
| gptkbp:conflict |
gptkb:competition
|
| gptkbp:cultural_diversity |
commitment to diversity
|
| gptkbp:customer_base |
gptkb:healthcare_professionals
|
| gptkbp:customer_support |
dedicated customer service teams
|
| gptkbp:development |
diverse global workforce
|
| gptkbp:employees |
approximately 18,000
|
| gptkbp:employs |
thousands of people
|
| gptkbp:financial_performance |
strong growth
strong financial performance |
| gptkbp:focus_area |
aesthetics and therapeutics
|
| gptkbp:focuses_on |
neuroscience
dermatology ophthalmology urology gastroenterology medical aesthetics |
| gptkbp:founded |
gptkb:1983
|
| gptkbp:founded_in |
gptkb:1983
|
| gptkbp:founder |
gptkb:Dr._J._Michael_Bishop
|
| gptkbp:global_presence |
over 100 countries
|
| gptkbp:has_culture |
inclusive
|
| gptkbp:has_mission |
improve patient outcomes
|
| gptkbp:has_part |
gptkb:Allergan_Aesthetics
|
| gptkbp:has_partnerships_with |
various biotechnology companies
|
| gptkbp:has_product_line |
eye care products
urology products dermatological products gastrointestinal products neuroscience products injectable fillers ophthalmic pharmaceuticals |
| gptkbp:has_received |
numerous awards
|
| gptkbp:has_research_focus |
biologics
innovative therapies biosimilars development |
| gptkbp:headquartered_in |
gptkb:Irvine,_California
|
| gptkbp:headquarters |
gptkb:Irvine,_California
gptkb:Irvine,_California,_USA |
| gptkbp:healthcare |
therapeutics
|
| https://www.w3.org/2000/01/rdf-schema#label |
Allergan
|
| gptkbp:industry |
gptkb:pharmaceuticals
healthcare |
| gptkbp:innovation |
focus on innovative therapies
biologics and biosimilars |
| gptkbp:instruction_set |
strong
|
| gptkbp:invention |
numerous patents in pharmaceuticals
numerous pharmaceutical patents |
| gptkbp:investment |
active investor relations program
R& D R& D investments |
| gptkbp:is_committed_to |
community engagement
diversity and inclusion patient safety regulatory compliance sustainability clinical trials |
| gptkbp:known_for |
gptkb:Botox
gptkb:Juvederm gptkb:Latisse gptkb:Restasis gptkb:medical_devices ophthalmic products dermatological products breast implants Botulinum toxin products aesthetics portfolio |
| gptkbp:leadership |
ophthalmic products
leadership programs aesthetic medicine diverse team dermatological treatments urology treatments gastroenterology treatments neuroscience treatments |
| gptkbp:market_cap |
approximately $60 billion (2020)
|
| gptkbp:market_launch |
frequent
|
| gptkbp:market_position |
global
over 100 countries |
| gptkbp:marketing_strategy |
diversification
aggressive marketing strategies |
| gptkbp:offers |
gptkb:Skin
gptkb:medical_devices neurotoxins dermal fillers |
| gptkbp:operates_in |
global market
|
| gptkbp:parent_company |
gptkb:Abb_Vie_Inc.
|
| gptkbp:partnership |
academic institutions
|
| gptkbp:partnerships |
academic institutions
healthcare providers various healthcare organizations various pharmaceutical companies research organizations various biotech companies |
| gptkbp:philanthropy |
gptkb:Allergan_Foundation
|
| gptkbp:produces |
biosimilars
|
| gptkbp:products |
gptkb:Botox
gptkb:Cool_Sculpting gptkb:Juvederm gptkb:Restasis gptkb:botulism Dermal fillers Ophthalmic products eye care products dermatology products gastroenterology products Neurotoxin products neuroscience products medical aesthetics products |
| gptkbp:reach |
extensive
over 100 countries |
| gptkbp:regulatory_compliance |
FDA approved products
strict regulatory compliance |
| gptkbp:research_and_development |
$3.5 billion (2019)
|
| gptkbp:research_areas |
neurology
dermatology ophthalmology plastic surgery gastroenterology |
| gptkbp:research_focus |
biologics
small molecules innovative therapies biologics and biosimilars |
| gptkbp:revenue |
$16.1 billion (2019)
|
| gptkbp:social_responsibility |
community health initiatives
commitment to CSR |
| gptkbp:specializes_in |
neuroscience
dermatology ophthalmology gastroenterology eye care medical aesthetics |
| gptkbp:stock_exchange |
gptkb:NYSE
traded on NYSE |
| gptkbp:stock_symbol |
gptkb:AGN
NYSE: ABBV |
| gptkbp:subsidiaries |
gptkb:Allergan_Eye_Care
gptkb:Allergan_Medical gptkb:Allergan_Neuroscience gptkb:Allergan_Aesthetics Allergan Gastroenterology Abb Vie Medical |
| gptkbp:subsidiary |
gptkb:Abb_Vie
|
| gptkbp:supply_chain |
global supply chain management
|
| gptkbp:sustainability_efforts |
environmental responsibility
|
| gptkbp:sustainability_initiatives |
environmental responsibility
environmental responsibility programs |
| gptkbp:training |
comprehensive training programs
continuous development |
| gptkbp:vision |
transform lives through innovation.
|
| gptkbp:website |
www.allergan.com
|
| gptkbp:bfsParent |
gptkb:Abb_Vie
|
| gptkbp:bfsLayer |
4
|